Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 18, 2009, Pages 6590-6605

  Gillespie, Roger J ^a   Bamford, Samantha J ^a   Clay, Alex ^a   Gaur, Suneel ^a   Haymes, Tim ^a   Jackson, Philip S ^a   Jordan, Allan M ^a   Klenke, Burkhard ^a   Leonardi, Stefania ^a   Liu, Jeanette ^a   Mansell, Howard L ^a   Ng, Sean ^a   Saadi, Mona ^a   Simmonite, Heather ^a   Stratton, Gemma C ^a   Todd, Richard S ^a   Williamson, Douglas S ^a   Yule, Ian A ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

Adenosine receptor; Parkinson's disease; Pyrimidine carboxamide

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CYTOCHROME P450 1A2; HALOPERIDOL; N (1 ETHYL 1H IMIDAZOL 2 YLMETHYL) 2 AMINO (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; N (1 METHYL 1H PYRROL 2 YLMETHYL) 2 AMINO (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; N (6 METHYLPYRIDIN 2 YLMETHYL) 2 AMINO (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; N (IMIDAZOL 2 YLMETHYL) 2 AMINO (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; N (PYRROL 2 YLMETHYL) 2 AMINO (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; N [(PYRIDIN 2 YL)METHYL] 2 AMINO 6 (5 METHYL 2 FURYL)PYRIMIDINE 4 CARBOXAMIDE; PYRIMIDINE 4 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIQUID CHROMATOGRAPHY; LOCOMOTION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PARKINSON DISEASE; PLASMA PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; HUMANS; LOCOMOTION; MICE; PARKINSON DISEASE; PROTEIN BINDING; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69249160301     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.07.078     Document Type: Article

References (23)

1. Xu K., Bastia E., and Schwarzschild M. Pharmacol. Ther. 105 (2005) 267
2. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
3. Gillespie R.J., Bamford S.J., Guar S., Jordan A.M., Lepiniere J., Mansell H.L., and Stratton G.C. Bioorg. Med. Chem. Lett. 19 (2009) 2664
4. Rabasseda X., Sorbera L.A., Martin L., Leeson P.A., and Castaner J. Drugs Future 26 (2001) 20
5. LeWitt P.A., Guttman M., Tetrud J.W., Tuire P.J., Mori A., Chaikin P., and Sussman N.M. Ann. Neurol. 63 (2008) 295
6. http://www.kyowa-kirin.co.jp/english/news/kyowa/er080228_01.html; http://www.kyowa-kirin.co.jp/english/news/2009/e20090115_01.htm.
7. Gillespie, R. J.; Todd, R. S.; Stratton, G. C.; Jordan, A. M. PCT Int. Appl. WO2005079801, 2005; Gillespie, R. J.; Williamson, D. S. PCT Int. Appl. WO2005079800, 2005.
8. Gillespie R.J., Adams D.R., Benwell K., Bebbington D., Cliffe I.A., Dawson C.E., Dourish C.T., Fletcher A., Giles P.R., Gaur S., Jordan A.M., Knight A.R., Knutsen L.J.S., Lawrence A., Lerpiniere J., Misra A., Porter R.H.P., Pratt R.M., Shepherd R., Upton R., Ward S.E., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2916
9. Gillespie R.J., Cliffe I.A., Dawson C.E., Dourish C.T., Gaur S., Giles P.R., Jordan A.M., Knight A.R., Lawrence A., Lerpiniere J., Misra A., Pratt R.M., Todd R.S., Upton R., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2920
10. Gillespie R.J., Cliffe I.A., Dawson C.E., Dourish C.T., Gaur S., Jordan A.M., Knight A.R., Lerpiniere J., Misra A., Pratt R.M., Roffey J., Stratton G.C., Upton R., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2924
11. Gillespie R.J., Bamford S.J., Botting R., Comer M., Denny S., Gaur S., Griffin M., Jordan A.M., Knight A.R., Lerpiniere J., Leonardi S., Lightowler S., McAteer S., Merrett A., Misra A., Padfield A., Reece M., Saadi M., Selwood D.L., Stratton G.C., Surry D., Todd R., Tong X., Ruston V., Upton R., and Weiss S.M. J. Med. Chem. 52 (2009) 33
12. i determination, see:. Weiss S.M., Benwell K., Cliffe I.A., Gillespie R.J., Knight A.R., Lerpiniere J., Misra A., Pratt R.M., Revell D., Upton R., and Dourish C.T. Neurology 61 (2003) S101 All values are the mean of at least two separate values
13. Broughton H.B., and Watson I.A. J. Mol Graphics Modell. 23 (2004) 51
14. Dixon, J. A.; Nagarathnam, D.; Zhang, L.; Wang, C.; Yi, L.; Chen, Y.; Chen, J.; Bear, B. R.; Brands, M.; Hillisch, A.; PCT Int. Appl. WO2006099231, 2006; Nagarathnam, D.; Dumas, J.; Hatoum-Mokdad, H.; Boyer, S.; Pluempe, H. PCT Int. Appl. WO2003062227, 2003.
15. Richardson C.M., Gillespie R.J., Williamson D.S., Jordan A.M., Fink A., Knight A.R., Sellwood D.M., and Misra A. Bioorg. Med. Chem Lett. 16 (2006) 5993
16. Kiselgof E., Tulshian D.B., Arik L., Zhang H., and Fawzi A. Bioorg. Med. Chem. Lett. 15 (2005) 2119
17. Davies G.D., Baiocchi F., Robins R.K., and Cheng C.C. J. Org. Chem. (1961) 2755
18. Flohr, A.; Norcross, R. D. U.S. Pat. Appl. 2004204584, 2004.
19. Emerson D.W., Titus R.L., and Gonzalez R.M. J. Org. Chem. 56 (1991) 5301
20. Emerson D.W., Titus R.L., and Gonzalez R.M. J. Org. Chem. 55 (1990) 3572
21. Gershon H., Braun R., Scala A., and Rodin R. J. Med. Chem. 7 (1964) 808
22. Data not shown.
23. Bezard E., Imbert C., and Gross C.E. Rev. Neurosci. 9 (1998) 71